Johnson & Johnson increased its 2026 sales forecast to $101.2 billion and raised adjusted EPS guidance to $11.10 after reporting a 6% operational sales growth in Q3. The growth was driven by strong performance in its Innovative Medicine division, especially cancer treatments, and gains in MedTech products. Despite a 7.5% drop in adjusted EPS for the quarter due to acquisitions and collaborations, the company expects momentum to continue with investments targeting double-digit growth by decade's end. Regulatory approvals for new products also support future growth prospects.
Johnson & Johnson shares are currently trading at USD 249.26 on Pluang, down 5.49% in the last day. The stock shows a dividend yield of 2.03% and a market cap of $635.56 billion as of Oct 13, 2026 22:22 WIB.
Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...
Johnson & Johnson's TREMFYA (guselkumab) demonstrated consistent combined fistula remission rates of up to 28% at Week 24 in adults with Crohn's disease and perianal fistula, outperforming placebo at 10%. New Phase 3 subgroup analyses from the FUZION...
Johnson & Johnson announced three-year data from Phase 3 GALAXI 2 and 3 studies showing TREMFYA (guselkumab) provides durable clinical remission rates up to 94% and endoscopic remission up to 61% in adults with moderately to severely active Crohn's d...
As of October 2026, U.S. Treasury bills yield between 3.98% and 4.44% depending on maturity, surpassing Johnson & Johnson's 2.05% dividend yield. Treasury bills guarantee fixed returns until maturity but carry reinvestment and inflation risks, while ...
Johnson & Johnson and UnitedHealth Group both released their third-quarter 2026 earnings on the same morning, highlighting key trends in drug costs, insurance margins, and sector outlook. Johnson & Johnson showed steady revenue growth with strong per...
